News

Under the agreement, GSK will receive a 19.9% stake in Orchard and get a seat on its board.  The acquisition of the portfolio, which includes both approved and investigational therapies

The personalized vaccine is made from patients’ own immune cells, which are exposed in the laboratory to the contents of the patients’ tumor cells, and then injected into

Through the partnership agreement, Mylan will leverage its regulatory platform to seek approval and commercialize the product in Europe. Humira is a TNF-inhibitor aimed at treating multiple chronic inflammatory

As per the terms of the all-cash deal, US-based Alexion via a subsidiary will pay SEK232 ($27.84) for each share of Wilson Therapeutics. The Swedish company is developing

The transaction complements Promethera’s pipeline with an innovative antibody-based drug candidate that specifically binds to the tumor necrosis factor receptor 1 (TNF-R1). Combining this novel therapeutic strategy with

The two companies will also partner on the development and commercialization of GA Depot. GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting

Pfizer said that the committee has asked it to stop the trial, dubbed Atlas, at a planned interim analysis after finding it to be futile. The recommendation had

The funding will be used to carry out prostate cancer studies over the next five years. More than 40,000 men will be recruited in the prostate cancer trials

New investors include Cormorant Asset Management, Deerfield Management, Fidelity Management and Research Company, Hillhouse Capital, NS Investment, OrbiMed, Sirona Capital, and Venrock Healthcare Partners. Current investors, including The